Chinese biopharma firm Adlai Nortye nets $100m in Series C round

Chinese biopharma firm Adlai Nortye nets $100m in Series C round

Laboratory equipment. Photo: Pixabay

Adlai Nortye, a China-based clinical-stage biopharmaceutical firm that develops immuno-oncology medicines, on Monday announced the completion of nearly $100 million in a Series C round of financing.